<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122130</url>
  </required_header>
  <id_info>
    <org_study_id>0252-06/2021</org_study_id>
    <nct_id>NCT05122130</nct_id>
  </id_info>
  <brief_title>Effect of Melatonin on Palatal Wound Healing (Randomized Controlled Clinical Trial)</brief_title>
  <official_title>EFFECT OF TOPICALLY APPLIED MELATONIN (N-ACETYL-5-METHOXY TRYPTAMINE) LOADED GELATIN SPONGE ON PALATAL WOUND HEALING (RANDOMIZED CONTROLLED CLINICAL TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salma Nabil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effect of topical melatonin loaded gelatin sponge on&#xD;
      donor palatal site healing, after palatal graft harvesting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autogenous soft tissue grafts can be considered the gold standard treatment for many&#xD;
      muco-gingival problems. The most common site for harvesting soft tissue grafts is the palate.&#xD;
      Many harvesting techniques have emerged, but the epithelialized graft harvesting technique is&#xD;
      one of the most reliable and effective techniques as it imparts the superficial section of&#xD;
      the connective tissue which contains the highest amount of lamina propria. Unfortunately, it&#xD;
      leaves an open palatal wound healed by secondary intention, increasing pain and&#xD;
      post-operative morbidity. In order to overcome these inadequacies we will cover the donor&#xD;
      site with melatonin loaded gelatin sponge and evaluate its effect on the healing process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>This study will be double-blinded where the patients and the statistician will be unaware of the treatment assignment till the end of the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>palatal wound healing</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Standardized clinical photographs of the palatal surgical sites will be taken and will be imported into a software program (ImageJ 1.49v) and wound areas will be calculated by computerized planimetry (Difference in remaining wound area [mm2])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of pain</measure>
    <time_frame>Up 2 weeks</time_frame>
    <description>by visual analogue scale Patients will be asked to grade the severity of their symptoms on VAS that ranges from (0-100 mm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>Melatonin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin loaded Carbopol hydrogel will be synthesized as follows: 1 gm of Carbopol will be dissolved in 100 ml deionized water while stirring at 600 rpm for 25°C. Melatonin (3gm) will be dissolved in 1 ml ethanol and added to the formed gel while stirring at 600 rpm at 25 °C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed and it will be loaded on gelatin sponge and will be applied to the donor site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>•Topical placebo carbopol gel will be prepared as follows: 1 gm of Carbopol will be dissolved in 100ml deionized water while stirring at 600 rpm for 25°C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>The donor site will be dressed with melatonin loaded gelatin sponge</description>
    <arm_group_label>Melatonin group</arm_group_label>
    <other_name>N-ACETYL-5-METHOXY TRYPTAMINE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbopol</intervention_name>
    <description>The donor site will be dressed with carbopol loaded gelatin sponge (placebo).</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients who have at least one site of natural dentition or dental implants that need&#xD;
             to be treated by free palatal graft surgery for indications including progressive&#xD;
             recession, planned prosthodontics, presence of a mucogingival deformity, or a lack of&#xD;
             keratinized gingiva.&#xD;
&#xD;
          2. Patients who have at least 4 mm thickness of palatal mucosa (at donor site)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of smoking.&#xD;
&#xD;
          2. Patients who have any known disease that interfere with periodontal surgery.&#xD;
&#xD;
          3. Patients who have any dermal or autoimmune diseases.&#xD;
&#xD;
          4. Patients who have any previous adverse reactions to the products (or similar products)&#xD;
             used in this study.&#xD;
&#xD;
          5. Pregnant and lactating women.&#xD;
&#xD;
          6. Patients who have a palatal infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>salma Nabil, BDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salma Nabil, BDS</last_name>
    <phone>01099076119</phone>
    <phone_ext>002</phone_ext>
    <email>Salma.Nabil.dent@alexu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed haggag, BDS</last_name>
    <phone>01066292227</phone>
    <phone_ext>002</phone_ext>
    <email>ahmedhagag90@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <phone>4869690</phone>
    </contact>
    <investigator>
      <last_name>Salma Nabil, BDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gehan Kotry, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>yasmine Gaweesh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Salma Nabil</investigator_full_name>
    <investigator_title>Demonstrator</investigator_title>
  </responsible_party>
  <keyword>Gelatin sponge, melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

